ruxolitinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	4190	941678-49-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ruxolitinib jakafi INCB 018424 ruxolitinib phosphate jakavi	a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Although some small studies have suggested possibility of benefit from ruxolitinib in patients with COVID-19, it is not recommended the use of JAK inhibitors other than baricitinib for the treatment of COVID-19. Molecular weight: 306.37 Formula: C17H18N6 CLOGP: 2.29 LIPINSKI: 0 HAC: 6 HDO: 1 TPSA: 83.18 ALOGS: -3.42 ROTB: 4 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ruxolitinib
jakafi
INCB 018424
ruxolitinib phosphate
jakavi

a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Although some small studies have suggested possibility of benefit from ruxolitinib in patients with COVID-19, it is not recommended the use of JAK inhibitors other than baricitinib for the treatment of COVID-19.

Molecular weight: 306.37
Formula: C17H18N6
CLOGP: 2.29
LIPINSKI: 0
HAC: 6
HDO: 1
TPSA: 83.18
ALOGS: -3.42
ROTB: 4

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O

ADMET properties:

Property	Value	Reference
fu (Fraction unbound in plasma)	0.08 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company	Orphan
Aug. 23, 2012	EMA	NOVARTIS EUROPHARM LIMITED
Nov. 16, 2011	FDA	INCYTE CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	428.49	17.79	315	17880	115807	63355020
Splenomegaly	427.18	17.79	149	18046	11008	63459819
Platelet count increased	418.72	17.79	166	18029	17545	63453282
Haemoglobin decreased	375.99	17.79	320	17875	145165	63325662
Anaemia	240.95	17.79	354	17841	293076	63177751
Full blood count abnormal	199.07	17.79	120	18075	31597	63439230
White blood cell count increased	181.52	17.79	133	18062	48428	63422399
Death	171.57	17.79	349	17846	374032	63096795
Product dose omission issue	145.38	17.79	249	17946	234064	63236763
Weight increased	134.83	17.79	256	17939	260536	63210291
Red blood cell count decreased	126.87	17.79	100	18095	40545	63430282
Contusion	107.13	17.79	170	18025	149874	63320953
Acute myeloid leukaemia	100.18	17.79	62	18133	17085	63453742
Thrombocytopenia	96.71	17.79	163	18032	150994	63319833
Cytomegalovirus infection reactivation	96.57	17.79	38	18157	3925	63466902
Febrile neutropenia	86.99	17.79	136	18059	118313	63352514
Increased appetite	86.23	17.79	46	18149	9584	63461243
Myelofibrosis	79.13	17.79	25	18170	1352	63469475
Flatulence	76.64	17.79	70	18125	34632	63436195
Thrombotic microangiopathy	71.54	17.79	42	18153	10519	63460308
Epstein-Barr virus infection reactivation	65.22	17.79	19	18176	779	63470048
Drug hypersensitivity	61.94	17.79	8	18187	310679	63160148
Graft versus host disease in gastrointestinal tract	61.58	17.79	26	18169	3215	63467612
Haematocrit decreased	60.23	17.79	65	18130	39275	63431552
Dizziness	59.41	17.79	262	17933	429663	63041164
Arthropathy	52.11	17.79	4	18191	234788	63236039
Maternal exposure during pregnancy	48.13	17.79	4	18191	220058	63250769
Bone pain	47.59	17.79	68	18127	54573	63416254
Graft versus host disease in liver	46.52	17.79	14	18181	643	63470184
Abdominal distension	44.55	17.79	85	18110	86530	63384297
Blood lactate dehydrogenase increased	42.23	17.79	42	18153	23074	63447753
White blood cell count decreased	41.65	17.79	110	18085	138994	63331833
Platelet count abnormal	41.62	17.79	20	18175	3344	63467483
Graft versus host disease in skin	41.27	17.79	19	18176	2886	63467941
Therapeutic product effect decreased	40.93	17.79	4	18191	193183	63277644
Chronic graft versus host disease	40.08	17.79	19	18176	3083	63467744
Epistaxis	39.42	17.79	73	18122	72652	63398175
Night sweats	38.53	17.79	58	18137	48756	63422071
Transfusion	38.17	17.79	33	18162	15184	63455643
Product use in unapproved indication	37.75	17.79	125	18070	178955	63291872
Therapeutic response unexpected	35.97	17.79	35	18160	18724	63452103
Fungal endocarditis	34.83	17.79	9	18186	234	63470593
Glossodynia	34.68	17.79	5	18190	178871	63291956
Adenovirus infection	34.64	17.79	18	18177	3553	63467274
JC virus infection	34.19	17.79	15	18180	2036	63468791
Hypersensitivity	33.91	17.79	21	18174	292664	63178163
Chronic graft versus host disease oral	33.75	17.79	8	18187	144	63470683
Fatigue	33.69	17.79	395	17800	887633	62583194
Exposure during pregnancy	33.53	17.79	3	18192	155544	63315283
Wound	33.00	17.79	4	18191	163259	63307568
Primary myelofibrosis	32.99	17.79	7	18188	74	63470753
Gout	31.72	17.79	28	18167	13243	63457584
Haemorrhage	31.51	17.79	60	18135	60962	63409865
Splenectomy	31.35	17.79	10	18185	558	63470269
Graft versus host disease	30.99	17.79	21	18174	6742	63464085
Bronchopulmonary aspergillosis	30.76	17.79	23	18172	8612	63462215
Infective aneurysm	30.19	17.79	9	18186	400	63470427
Chronic graft versus host disease in eye	29.96	17.79	7	18188	118	63470709
Musculoskeletal stiffness	29.85	17.79	8	18187	184610	63286217
Leukocytosis	29.84	17.79	37	18158	25898	63444929
Blast cell count increased	29.42	17.79	9	18186	437	63470390
Leukaemia	29.19	17.79	17	18178	4191	63466636
Post transplant lymphoproliferative disorder	28.89	17.79	18	18177	5013	63465814
Spleen disorder	28.86	17.79	11	18184	1042	63469785
Acute graft versus host disease	28.39	17.79	17	18178	4411	63466416
Muscle spasms	27.71	17.79	103	18092	156047	63314780
Drug intolerance	27.21	17.79	29	18166	308632	63162195
Iron overload	26.94	17.79	10	18185	881	63469946
Asthenia	26.89	17.79	195	18000	383409	63087418
Haemophagocytic lymphohistiocytosis	26.56	17.79	23	18172	10604	63460223
Eye infection bacterial	25.97	17.79	7	18188	215	63470612
Second primary malignancy	25.73	17.79	20	18175	7933	63462894
Drug ineffective	25.71	17.79	185	18010	1044580	62426247
Joint swelling	25.46	17.79	34	18161	327632	63143195
Gastroenteritis adenovirus	24.90	17.79	7	18188	252	63470575
Condition aggravated	24.47	17.79	49	18146	402168	63068659
Pancytopenia	24.40	17.79	72	18123	96861	63373966
Toxicity to various agents	24.39	17.79	21	18174	247229	63223598
Cystitis haemorrhagic	24.31	17.79	15	18180	4108	63466719
Cytomegalovirus infection	24.28	17.79	30	18165	20922	63449905
Overdose	22.81	17.79	3	18192	115075	63355752
Herpes zoster	22.45	17.79	63	18132	82399	63388428
Babesiosis	21.16	17.79	6	18189	223	63470604
Pulmonary haemorrhage	20.96	17.79	17	18178	7164	63463663
Sepsis	20.80	17.79	93	18102	153030	63317797
Blast cells present	20.65	17.79	7	18188	473	63470354
Urticaria	20.46	17.79	11	18184	165791	63305036
Adenocarcinoma metastatic	20.46	17.79	5	18190	103	63470724
Basophil percentage increased	20.28	17.79	5	18190	107	63470720
Red blood cell count increased	20.09	17.79	12	18183	3100	63467727
Encopresis	20.02	17.79	5	18190	113	63470714
Promyelocyte count increased	19.40	17.79	3	18192	3	63470824
Cytopenia	19.22	17.79	20	18175	11581	63459246
Aspergillus infection	19.19	17.79	17	18178	8076	63462751
Swelling	19.02	17.79	31	18164	275347	63195480
Acute graft versus host disease in skin	18.94	17.79	12	18183	3440	63467387
Headache	18.56	17.79	269	17926	632972	62837855
Encephalitis fungal	18.54	17.79	4	18191	46	63470781
Extramedullary haemopoiesis	17.95	17.79	4	18191	54	63470773
Oral herpes	17.81	17.79	29	18166	26045	63444782

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Splenomegaly	379.75	15.56	187	21867	14930	34919947
Platelet count decreased	298.65	15.56	372	21682	119345	34815532
Haemoglobin decreased	234.34	15.56	332	21722	120440	34814437
Febrile neutropenia	215.23	15.56	341	21713	136508	34798369
Death	201.09	15.56	627	21427	397422	34537455
Anaemia	194.28	15.56	443	21611	232892	34701985
Platelet count increased	184.58	15.56	99	21955	9427	34925450
White blood cell count increased	150.09	15.56	156	21898	40995	34893882
Acute myeloid leukaemia	132.11	15.56	102	21952	18168	34916709
Second primary malignancy	122.81	15.56	71	21983	7815	34927062
Full blood count abnormal	117.36	15.56	96	21958	18572	34916305
Iron overload	92.65	15.56	34	22020	1299	34933578
Adenovirus infection	83.63	15.56	48	22006	5209	34929668
Product dose omission issue	82.76	15.56	212	21842	119499	34815378
Red blood cell count decreased	73.17	15.56	91	21963	28999	34905878
Graft versus host disease in skin	71.02	15.56	39	22015	3886	34930991
Contusion	70.30	15.56	100	21954	36264	34898613
Scleroderma	66.54	15.56	28	22026	1544	34933333
Myelofibrosis	65.88	15.56	28	22026	1583	34933294
Night sweats	61.80	15.56	65	21989	17287	34917590
Graft versus host disease in gastrointestinal tract	59.58	15.56	34	22020	3649	34931228
Blast cell count increased	55.18	15.56	22	22032	1056	34933821
Graft versus host disease in liver	54.78	15.56	23	22031	1261	34933616
Graft versus host disease	53.45	15.56	48	22006	10521	34924356
Acute leukaemia	53.45	15.56	22	22032	1147	34933730
Toxicity to various agents	52.04	15.56	31	22023	200331	34734546
Drug interaction	51.96	15.56	40	22014	225906	34708971
Completed suicide	49.93	15.56	3	22051	98165	34836712
Nocardiosis	49.65	15.56	31	22023	3920	34930957
Cytomegalovirus infection reactivation	49.29	15.56	34	22020	5084	34929793
Epistaxis	48.57	15.56	111	21943	58140	34876737
Acute graft versus host disease in liver	47.27	15.56	22	22032	1544	34933333
Fatigue	47.05	15.56	396	21658	370257	34564620
Thrombocytopenia	46.17	15.56	208	21846	156039	34778838
Acute graft versus host disease in intestine	43.80	15.56	25	22029	2683	34932194
Enterovirus infection	43.20	15.56	18	22036	968	34933909
Acute graft versus host disease	42.02	15.56	34	22020	6469	34928408
Graft versus host disease in lung	40.97	15.56	15	22039	569	34934308
Product use in unapproved indication	40.54	15.56	164	21890	117335	34817542
Haematocrit decreased	39.45	15.56	72	21982	32144	34902733
Immunosuppression	38.72	15.56	32	22022	6272	34928605
Pneumonia	38.59	15.56	373	21681	362254	34572623
Overdose	37.95	15.56	6	22048	91053	34843824
Leukocytosis	37.68	15.56	60	21994	24005	34910872
Transfusion	37.63	15.56	36	22018	8549	34926328
Platelet count abnormal	36.90	15.56	23	22031	2899	34931978
Leukaemia	36.12	15.56	27	22027	4576	34930301
Pneumatosis intestinalis	35.30	15.56	25	22029	3898	34930979
Eye infection fungal	35.20	15.56	12	22042	368	34934509
Parainfluenzae virus infection	35.05	15.56	22	22032	2808	34932069
Early satiety	34.80	15.56	14	22040	688	34934189
Bradycardia	33.72	15.56	4	22050	75414	34859463
NPM1 gene mutation	33.65	15.56	9	22045	117	34934760
Flatulence	33.39	15.56	53	22001	21145	34913732
Pyrexia	32.71	15.56	337	21717	332676	34602201
Pneumoretroperitoneum	32.27	15.56	9	22045	138	34934739
White blood cell count decreased	31.94	15.56	132	21922	95313	34839564
Chimerism	31.94	15.56	10	22044	233	34934644
Aspergillus infection	31.87	15.56	39	22015	12215	34922662
Blast cell crisis	30.57	15.56	8	22046	95	34934782
Hypotension	30.07	15.56	59	21995	221590	34713287
Weight increased	29.83	15.56	127	21927	92906	34841971
Haemosiderosis	29.67	15.56	10	22044	296	34934581
Enterococcal bacteraemia	29.31	15.56	17	22037	1880	34932997
Bronchiolitis obliterans syndrome	29.27	15.56	9	22045	197	34934680
Chronic graft versus host disease	28.54	15.56	23	22031	4350	34930527
Cerebral artery embolism	28.44	15.56	13	22041	875	34934002
Thyroid gland abscess	28.21	15.56	7	22047	66	34934811
Stenotrophomonas infection	27.64	15.56	17	22037	2093	34932784
Retinal ischaemia	27.37	15.56	10	22044	377	34934500
Respiratory syncytial virus infection	27.05	15.56	23	22031	4686	34930191
Septic embolus	26.91	15.56	14	22040	1251	34933626
Myeloproliferative neoplasm	26.84	15.56	11	22043	567	34934310
Splenectomy	26.23	15.56	10	22044	425	34934452
Necrotising retinitis	25.94	15.56	12	22042	830	34934047
Squamous cell carcinoma	25.85	15.56	34	22020	11441	34923436
Infectious thyroiditis	25.76	15.56	7	22047	97	34934780
Epstein-Barr virus infection reactivation	25.75	15.56	13	22041	1091	34933786
Splenic infarction	25.37	15.56	16	22038	2059	34932818
Procedural pneumothorax	25.17	15.56	6	22048	47	34934830
Emphysematous cholecystitis	25.06	15.56	6	22048	48	34934829
Bacterial sepsis	24.89	15.56	23	22031	5227	34929650
Blast cells present	24.82	15.56	10	22044	493	34934384
Varicella zoster virus infection	24.81	15.56	15	22039	1791	34933086
Cardio-respiratory arrest	24.54	15.56	3	22051	55270	34879607
Bacterial translocation	24.34	15.56	9	22045	351	34934526
Syncope	23.91	15.56	14	22040	91437	34843440
Blood product transfusion dependent	23.36	15.56	9	22045	394	34934483
Infusion related reaction	23.26	15.56	3	22051	53054	34881823
Spleen disorder	23.24	15.56	12	22042	1055	34933822
Haemorrhage	22.96	15.56	78	21976	51292	34883585
Rhinovirus infection	22.68	15.56	20	22034	4279	34930598
Enterocolitis infectious	20.55	15.56	13	22041	1682	34933195
Haematocrit increased	20.26	15.56	14	22040	2099	34932778
Drug hypersensitivity	20.12	15.56	13	22041	80516	34854361
Serum ferritin increased	20.07	15.56	22	22032	6124	34928753
Seizure	19.98	15.56	22	22032	104835	34830042
Serum ferritin abnormal	19.93	15.56	7	22047	235	34934642
Confusional state	19.85	15.56	38	22016	144122	34790755
Steroid diabetes	19.78	15.56	14	22040	2181	34932696
Blood immunoglobulin G decreased	19.63	15.56	12	22042	1461	34933416
Acute graft versus host disease in skin	19.44	15.56	20	22034	5181	34929696
Skin cancer	19.41	15.56	28	22026	10269	34924608
Haematoma	19.37	15.56	47	22007	25558	34909319
Red blood cell count increased	18.79	15.56	12	22042	1577	34933300
Gout	18.66	15.56	39	22015	19214	34915663
Pancytopenia	18.57	15.56	113	21941	95044	34839833
Rhabdomyolysis	18.44	15.56	10	22044	68153	34866724
Increased appetite	18.28	15.56	23	22031	7406	34927471
Herpes zoster	17.87	15.56	55	21999	34344	34900533
Infection	17.76	15.56	108	21946	90807	34844070
Portal hypertension	17.73	15.56	17	22037	4045	34930832
Therapeutic response unexpected	17.62	15.56	26	22028	9731	34925146
Depressed level of consciousness	17.45	15.56	3	22051	42838	34892039
Skin lesion	17.35	15.56	41	22013	21920	34912957
Asthma	17.34	15.56	3	22051	42653	34892224
Neutrophil count decreased	17.33	15.56	71	21983	51033	34883844
Basophil count increased	17.31	15.56	8	22046	552	34934325
Haematoma infection	17.31	15.56	10	22044	1098	34933779
Malignant neoplasm progression	17.30	15.56	18	22036	88028	34846849
Therapy non-responder	17.10	15.56	59	21995	39087	34895790
Urticaria	17.10	15.56	9	22045	62368	34872509
Plasma cell myeloma	17.00	15.56	3	22051	42034	34892843
Central nervous system haemorrhage	16.83	15.56	5	22049	97	34934780
SARS-CoV-2 RNA	16.82	15.56	4	22050	31	34934846
Bone pain	16.76	15.56	39	22015	20647	34914230
Hallucination	16.37	15.56	6	22048	51492	34883385
Fungal infection	16.29	15.56	33	22021	15902	34918975
Cytopenia	16.29	15.56	29	22025	12694	34922183
Chest discomfort	16.27	15.56	7	22047	54523	34880354
Pneumonia respiratory syncytial viral	16.23	15.56	9	22045	914	34933963
Anorectal cellulitis	16.19	15.56	4	22050	37	34934840
Loss of consciousness	16.13	15.56	17	22037	82650	34852227
Microangiopathy	15.95	15.56	9	22045	945	34933932
Chronic graft versus host disease in skin	15.77	15.56	9	22045	965	34933912
Epstein-Barr viraemia	15.75	15.56	10	22044	1302	34933575
Thrombocytosis	15.71	15.56	16	22038	4096	34930781

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Splenomegaly	621.47	14.52	254	31993	20500	79691641
Platelet count decreased	579.98	14.52	539	31708	194125	79518016
Haemoglobin decreased	505.42	14.52	531	31716	221588	79490553
Platelet count increased	428.51	14.52	200	32047	22206	79689935
Febrile neutropenia	388.27	14.52	472	31775	230527	79481614
Anaemia	345.06	14.52	632	31615	444383	79267758
Death	278.99	14.52	668	31579	565846	79146295
White blood cell count increased	216.48	14.52	204	32043	74429	79637712
Acute myeloid leukaemia	164.18	14.52	120	32127	30765	79681376
Full blood count abnormal	155.96	14.52	130	32117	40344	79671797
Red blood cell count decreased	151.25	14.52	149	32098	57364	79654777
Graft versus host disease in gastrointestinal tract	147.61	14.52	65	32182	6291	79705850
Thrombocytopenia	139.94	14.52	322	31925	264937	79447204
Cytomegalovirus infection reactivation	139.82	14.52	69	32178	8647	79703494
Myelofibrosis	138.34	14.52	48	32199	2452	79709689
Graft versus host disease in skin	124.74	14.52	57	32190	6016	79706125
Contusion	110.53	14.52	208	32039	148568	79563573
Adenovirus infection	109.72	14.52	58	32189	8389	79703752
Graft versus host disease in liver	106.10	14.52	36	32211	1718	79710423
Haematocrit decreased	97.34	14.52	122	32125	61190	79650951
Product use in unapproved indication	96.53	14.52	270	31977	250089	79462052
Graft versus host disease	92.82	14.52	64	32183	14962	79697179
Product dose omission issue	92.54	14.52	264	31983	247273	79464868
Second primary malignancy	88.35	14.52	61	32186	14289	79697852
Epstein-Barr virus infection reactivation	88.25	14.52	32	32215	1860	79710281
Completed suicide	86.03	14.52	3	32244	245764	79466377
Iron overload	84.99	14.52	31	32216	1833	79710308
Infusion related reaction	79.92	14.52	3	32244	230234	79481907
Acute graft versus host disease	74.10	14.52	48	32199	10119	79702022
Drug hypersensitivity	72.69	14.52	16	32231	298900	79413241
Rheumatoid arthritis	71.40	14.52	3	32244	208467	79503674
Epistaxis	70.78	14.52	146	32101	111369	79600772
Blast cell count increased	70.10	14.52	25	32222	1385	79710756
White blood cell count decreased	69.53	14.52	200	32047	188088	79524053
Acute leukaemia	65.17	14.52	25	32222	1701	79710440
Toxicity to various agents	64.45	14.52	46	32201	421494	79290647
Night sweats	63.29	14.52	91	32156	52004	79660137
Flatulence	63.05	14.52	82	32165	42642	79669499
Thrombotic microangiopathy	62.02	14.52	57	32190	20112	79692029
Leukocytosis	61.95	14.52	82	32165	43373	79668768
Aspergillus infection	60.58	14.52	55	32192	19106	79693035
Acute graft versus host disease in intestine	58.95	14.52	30	32217	4011	79708130
Platelet count abnormal	56.48	14.52	31	32216	4831	79707310
Enterovirus infection	55.41	14.52	23	32224	1924	79710217
Weight increased	54.21	14.52	239	32008	277147	79434994
Graft versus host disease in lung	52.36	14.52	18	32229	894	79711247
Pyrexia	52.04	14.52	459	31788	678250	79033891
Nocardiosis	49.40	14.52	30	32217	5649	79706492
Pneumonia	48.79	14.52	443	31804	659803	79052338
Overdose	48.71	14.52	8	32239	184198	79527943
Arthropathy	48.41	14.52	7	32240	177104	79535037
Early satiety	47.82	14.52	19	32228	1420	79710721
Increased appetite	47.21	14.52	39	32208	11939	79700202
Transfusion	46.52	14.52	50	32197	21280	79690861
Hypersensitivity	46.49	14.52	24	32223	262215	79449926
Bronchiolitis obliterans syndrome	46.32	14.52	13	32234	326	79711815
Fatigue	45.89	14.52	575	31672	929152	78782989
Blood lactate dehydrogenase increased	44.07	14.52	66	32181	39104	79673037
Pneumatosis intestinalis	43.69	14.52	29	32218	6368	79705773
Therapeutic product effect decreased	43.58	14.52	7	32240	163856	79548285
Maternal exposure during pregnancy	43.52	14.52	3	32244	136535	79575606
Synovitis	43.50	14.52	5	32242	150729	79561412
Chimerism	43.41	14.52	12	32235	284	79711857
Drug interaction	43.31	14.52	63	32184	415120	79297021
Cytomegalovirus infection	42.58	14.52	68	32179	42576	79669565
Acute graft versus host disease in liver	42.39	14.52	19	32228	1916	79710225
Chronic graft versus host disease	42.15	14.52	29	32218	6752	79705389
NPM1 gene mutation	41.80	14.52	10	32237	130	79712011
Pancytopenia	40.42	14.52	153	32094	165592	79546549
Bradycardia	37.88	14.52	5	32242	135552	79576589
Respiratory syncytial virus infection	37.87	14.52	31	32216	9371	79702770
Asthma	37.71	14.52	5	32242	135090	79577051
Respiratory failure	37.70	14.52	159	32088	180752	79531389
Sepsis	37.58	14.52	211	32036	269217	79442924
Musculoskeletal stiffness	37.53	14.52	12	32235	174996	79537145
Joint swelling	37.31	14.52	37	32210	288609	79423532
Babesiosis	36.63	14.52	11	32236	352	79711789
Eye infection fungal	36.54	14.52	12	32235	517	79711624
Cystitis haemorrhagic	36.43	14.52	30	32217	9142	79702999
Myeloproliferative neoplasm	36.18	14.52	14	32233	975	79711166
Leukaemia	36.03	14.52	25	32222	5900	79706241
Rhinovirus infection	35.82	14.52	28	32219	7925	79704216
Splenectomy	35.42	14.52	13	32234	782	79711359
Immunosuppression	35.18	14.52	34	32213	12769	79699372
Cytopenia	34.65	14.52	42	32205	20341	79691800
Parainfluenzae virus infection	34.61	14.52	24	32223	5658	79706483
Acute graft versus host disease in skin	34.57	14.52	27	32220	7631	79704510
Pneumoretroperitoneum	34.43	14.52	9	32238	171	79711970
Urticaria	34.25	14.52	16	32231	185185	79526956
Basophil count increased	33.70	14.52	15	32232	1488	79710653
Drug intolerance	32.84	14.52	35	32212	264084	79448057
Bacteraemia	32.30	14.52	52	32195	32772	79679369
Herpes zoster	31.58	14.52	96	32151	92987	79619154
Pericarditis	31.25	14.52	3	32244	104233	79607908
Splenic infarction	30.96	14.52	19	32228	3645	79708496
Thyroid gland abscess	30.17	14.52	7	32240	79	79712062
Exposure during pregnancy	30.08	14.52	3	32244	101129	79611012
Blast cells present	29.85	14.52	12	32235	925	79711216
Enterocolitis infectious	29.80	14.52	17	32230	2852	79709289
Bone pain	29.66	14.52	68	32179	55674	79656467
Steroid diabetes	29.17	14.52	18	32229	3488	79708653
Diarrhoea haemorrhagic	28.82	14.52	31	32216	13203	79698938
Serum ferritin increased	28.67	14.52	27	32220	9820	79702321
Bronchopulmonary aspergillosis	28.63	14.52	40	32207	22254	79689887
Gout	28.26	14.52	42	32205	24707	79687434
Haemorrhage	28.17	14.52	91	32156	91027	79621114
Squamous cell carcinoma	27.89	14.52	33	32214	15589	79696552
Gastroenteritis adenovirus	27.76	14.52	9	32238	372	79711769
Injection site pain	27.66	14.52	9	32238	129829	79582312
Therapeutic response unexpected	27.44	14.52	37	32210	19909	79692232
Infectious thyroiditis	27.35	14.52	7	32240	122	79712019
BK virus infection	27.29	14.52	25	32222	8779	79703362
Fungal endocarditis	27.21	14.52	10	32237	604	79711537
Blood immunoglobulin G decreased	27.09	14.52	17	32230	3392	79708749
Therapeutic product effect incomplete	26.55	14.52	12	32235	141633	79570508
Emphysematous cholecystitis	26.52	14.52	6	32241	60	79712081
Septic shock	26.41	14.52	109	32138	122692	79589449
Septic embolus	26.40	14.52	14	32233	2037	79710104
Enterococcal bacteraemia	26.16	14.52	16	32231	3052	79709089
Confusional state	26.12	14.52	56	32191	317941	79394200
Blast cell crisis	26.12	14.52	7	32240	147	79711994
Thrombocytosis	26.02	14.52	24	32223	8502	79703639
Cardio-respiratory arrest	25.96	14.52	6	32241	108504	79603637
Infective aneurysm	25.66	14.52	11	32236	997	79711144
Hypotension	25.42	14.52	92	32155	440225	79271916
Varicella zoster virus infection	25.29	14.52	18	32229	4423	79707718
Spleen disorder	25.25	14.52	13	32234	1781	79710360
JC virus infection	25.08	14.52	17	32230	3864	79708277
Agitation	24.91	14.52	5	32242	99710	79612431
Haemosiderosis	24.90	14.52	9	32238	518	79711623
Tongue neoplasm malignant stage unspecified	24.89	14.52	11	32236	1073	79711068
Bacterial sepsis	24.87	14.52	23	32224	8175	79703966
Neutrophil count decreased	24.79	14.52	89	32158	93870	79618271
Retinal ischaemia	24.78	14.52	10	32237	778	79711363
Bacterial infection	24.77	14.52	45	32202	31235	79680906
Microangiopathy	24.77	14.52	13	32234	1852	79710289
Cerebral artery embolism	24.60	14.52	13	32234	1878	79710263
Basophil percentage increased	24.48	14.52	7	32240	188	79711953
Haematocrit increased	24.48	14.52	17	32230	4017	79708124
Procedural pneumothorax	24.35	14.52	6	32241	89	79712052
Anorectal cellulitis	24.16	14.52	6	32241	92	79712049
Asthenia	24.06	14.52	314	31933	511375	79200766
Red blood cell count increased	23.83	14.52	17	32230	4191	79707950
Depressed level of consciousness	23.82	14.52	5	32242	96647	79615494
Portal hypertension	23.64	14.52	21	32226	7087	79705054
Haemophagocytic lymphohistiocytosis	23.43	14.52	36	32211	21801	79690340
Necrotising retinitis	23.43	14.52	11	32236	1234	79710907
Pyomyositis	23.41	14.52	9	32238	616	79711525
Intentional product misuse	23.30	14.52	5	32242	95160	79616981
Stenotrophomonas infection	23.13	14.52	16	32231	3757	79708384
Bacterial translocation	22.91	14.52	9	32238	653	79711488
Promyelocyte count increased	22.88	14.52	5	32242	42	79712099
Drug ineffective for unapproved indication	22.44	14.52	58	32189	51180	79660961
Glossodynia	22.30	14.52	7	32240	103330	79608811
Staphylococcal bacteraemia	22.12	14.52	26	32221	12192	79699949
Extramedullary haemopoiesis	22.12	14.52	6	32241	132	79712009
Injection site erythema	21.57	14.52	3	32244	78194	79633947
Wound	21.53	14.52	10	32237	116169	79595972
Chronic graft versus host disease oral	21.36	14.52	6	32241	151	79711990
Primary myelofibrosis	21.24	14.52	6	32241	154	79711987
Lower respiratory tract infection	21.19	14.52	13	32234	129207	79582934
Suicidal ideation	20.89	14.52	3	32244	76337	79635804
Angioedema	20.78	14.52	3	32244	76032	79636109
Haematoma	20.75	14.52	57	32190	52138	79660003
Hepatic enzyme increased	20.74	14.52	26	32221	182584	79529557
Mucormycosis	20.51	14.52	21	32226	8448	79703693
Rhabdomyolysis	20.51	14.52	8	32239	103123	79609018
Mobility decreased	20.45	14.52	12	32235	122163	79589978
Venoocclusive disease	20.38	14.52	16	32231	4557	79707584
Epstein-Barr virus infection	20.23	14.52	27	32220	14389	79697752
Epstein-Barr viraemia	20.09	14.52	12	32235	2193	79709948
Eye infection bacterial	20.09	14.52	7	32240	362	79711779
Multiple organ dysfunction syndrome	20.05	14.52	99	32148	120147	79591994
Pulmonary haemorrhage	19.79	14.52	27	32220	14690	79697451
Myopathy	19.45	14.52	32	32215	20531	79691610
Red blood cell count abnormal	18.93	14.52	10	32237	1443	79710698
Syncope	18.90	14.52	27	32220	179422	79532719
Osteonecrosis	18.88	14.52	40	32207	31055	79681086
Condition aggravated	18.84	14.52	122	32125	501002	79211139
Pneumocystis jirovecii pneumonia	18.80	14.52	41	32206	32467	79679674
Wheezing	18.77	14.52	12	32235	116652	79595489
Loss of personal independence in daily activities	18.75	14.52	9	32238	102571	79609570
SARS-CoV-2 RNA	18.59	14.52	4	32243	31	79712110
Post transplant lymphoproliferative disorder	18.48	14.52	23	32224	11441	79700700
Dizziness	18.42	14.52	307	31940	526134	79186007
Erythropoiesis abnormal	18.38	14.52	7	32240	467	79711674
Myelocyte count increased	18.29	14.52	8	32239	761	79711380
Chronic graft versus host disease in skin	18.18	14.52	10	32237	1564	79710577
Neutrophil count increased	18.06	14.52	38	32209	29358	79682783
Haemoglobin abnormal	18.02	14.52	18	32229	7036	79705105
Venoocclusive liver disease	18.00	14.52	23	32224	11748	79700393
Cytomegalovirus colitis	17.93	14.52	15	32232	4670	79707471
Swelling	17.92	14.52	38	32209	216673	79495468
Acute myeloid leukaemia recurrent	17.64	14.52	13	32234	3370	79708771
Pneumonia fungal	17.29	14.52	22	32225	11188	79700953
Viraemia	17.20	14.52	12	32235	2857	79709284
Blood uric acid increased	17.20	14.52	24	32223	13336	79698805
Peripheral T-cell lymphoma unspecified recurrent	17.09	14.52	4	32243	47	79712094
Cardiac arrest	17.06	14.52	27	32220	172069	79540072
Metapneumovirus infection	17.01	14.52	10	32237	1774	79710367
Bone tuberculosis	17.01	14.52	7	32240	573	79711568
Cerebral aspergillosis	16.95	14.52	10	32237	1786	79710355
Hallucination	16.49	14.52	7	32240	85738	79626403
Pseudomonal bacteraemia	16.43	14.52	12	32235	3070	79709071
Helicobacter infection	16.39	14.52	4	32243	69700	79642441
Squamous cell carcinoma of skin	16.29	14.52	24	32223	14009	79698132
Erythema	16.18	14.52	42	32205	223248	79488893
Human herpesvirus 6 infection	16.16	14.52	15	32232	5355	79706786
Stress	16.12	14.52	6	32241	79606	79632535
Chronic graft versus host disease in liver	16.06	14.52	7	32240	660	79711481
Adenocarcinoma metastatic	15.93	14.52	5	32242	186	79711955
Disseminated blastomycosis	15.80	14.52	5	32242	191	79711950
Klebsiella infection	15.60	14.52	25	32222	15695	79696446
Sinusitis	15.57	14.52	35	32212	195466	79516675
Arthralgia	15.56	14.52	152	32095	571651	79140490
Serum ferritin abnormal	15.52	14.52	6	32241	417	79711724
Blood pressure fluctuation	15.50	14.52	4	32243	67141	79645000
Blood product transfusion dependent	15.41	14.52	6	32241	425	79711716
Staphylococcal infection	15.19	14.52	55	32192	58240	79653901
Upper respiratory tract infection	15.15	14.52	75	32172	91093	79621048
Anxiety	14.94	14.52	51	32196	248461	79463680

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D11AH09	DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Agents for dermatitis, excluding corticosteroids
ATC	L01EJ01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Janus-associated kinase (JAK) inhibitors
FDA MoA	N0000175076	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
FDA MoA	N0000190857	Janus Kinase Inhibitors
FDA EPC	N0000190858	Janus Kinase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:76617	BTK inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Splenomegaly	indication	16294009
Myelofibrosis	indication	52967002	DOID:4971
Vitiligo	indication	56727007	DOID:12306
Polycythemia vera	indication	109992005
Acute graft-versus-host disease	indication	402355000
Chronic graft-versus-host disease	indication	402356004
Myeloproliferative disorder	indication	425333006
Coronavirus infection	off-label use	186747009
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.44	acidic
pKa2	4.6	Basic
pKa3	2.37	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9079912	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	9814722	Dec. 12, 2026	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	10639310	Dec. 12, 2026	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	9079912	Dec. 12, 2026	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	9079912	Dec. 12, 2026	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	9974790	Dec. 12, 2026	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	9974790	Dec. 12, 2026	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	7598257	Dec. 24, 2027	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	10016429	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8822481	June 12, 2028	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR THE TREATMENT OF POLYCYTHEMIA VERA
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	8829013	June 12, 2028	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	10610530	June 12, 2028	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	10610530	June 12, 2028	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	8822481	June 12, 2028	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	8822481	June 12, 2028	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	10869870	May 20, 2031	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	10869870	May 20, 2031	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11219624	May 20, 2031	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11590136	May 20, 2031	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11590136	May 20, 2031	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11590138	June 10, 2040	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, IN THE ABSENCE OF PHOTOTHERAPY, WHEREIN THE VITILIGO AFFECTS AT LEAST ONE OF THE LOWER EXTREMITIES, TRUNK, AND FEET OF THE PATIENT
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11510923	Sept. 4, 2040	FOR TOPICAL TREATMENT OF MODERATE AD IN NON-IMMUNOCOMPROMISED PATIENTS, WITH BASELINE BSA OF 3-20% AND ITCH NRS SCORE OF ≥4, WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11590137	Sept. 4, 2040	FOR TOPICAL TREATMENT OF MODERATE AD IN NON-IMMUNOCOMPROMISED PATIENTS, WITH BASELINE BSA OF 3-20% AND ITCH NRS SCORE OF ≥4, WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	11602536	May 5, 2041	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, IN THE ABSENCE OF LASER OR PHOTOTHERAPY, WHEREIN THE VITILIGO AFFECTS AT LEAST ONE OF THE LOWER EXTREMITIES, TRUNK, AND FEET OF THE PATIENT

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	Sept. 21, 2024	NEW PRODUCT
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Sept. 22, 2024	ADDITION OF THE INDICATION OF TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Sept. 22, 2024	ADDITION OF THE INDICATION OF TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	March 21, 2025	PEDIATRIC EXCLUSIVITY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	March 22, 2025	PEDIATRIC EXCLUSIVITY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	March 22, 2025	PEDIATRIC EXCLUSIVITY
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	July 18, 2025	INDICATED FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Dec. 19, 2025	REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Dec. 19, 2025	REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Dec. 19, 2025	REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Dec. 19, 2025	REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Dec. 19, 2025	REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
EQ 1.5% BASE	OPZELURA	INCYTE CORP	N215309	Sept. 21, 2021	RX	CREAM	TOPICAL	Jan. 18, 2026	PEDIATRIC EXCLUSIVITY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	May 24, 2026	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	May 24, 2026	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	May 24, 2026	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	May 24, 2026	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	May 24, 2026	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	June 19, 2026	PEDIATRIC EXCLUSIVITY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	June 19, 2026	PEDIATRIC EXCLUSIVITY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	June 19, 2026	PEDIATRIC EXCLUSIVITY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	June 19, 2026	PEDIATRIC EXCLUSIVITY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	June 19, 2026	PEDIATRIC EXCLUSIVITY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Nov. 24, 2026	PEDIATRIC EXCLUSIVITY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Nov. 24, 2026	PEDIATRIC EXCLUSIVITY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Nov. 24, 2026	PEDIATRIC EXCLUSIVITY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Nov. 24, 2026	PEDIATRIC EXCLUSIVITY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Nov. 24, 2026	PEDIATRIC EXCLUSIVITY
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Sept. 22, 2028	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Sept. 22, 2028	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Sept. 22, 2028	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Sept. 22, 2028	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	Sept. 22, 2028	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
EQ 10MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY
EQ 15MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY
EQ 20MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY
EQ 25MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY
EQ 5MG BASE	JAKAFI	INCYTE CORP	N202192	Nov. 16, 2011	RX	TABLET	ORAL	March 22, 2029	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Tyrosine-protein kinase JAK2	Kinase	O60674	JAK2_HUMAN	INHIBITOR	Kd	10.44	CHEMBL	CHEMBL
Tyrosine-protein kinase JAK1	Kinase	P23458	JAK1_HUMAN	INHIBITOR	Ki	10.05	CHEMBL	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	5.96	CHEMBL
Mast/stem cell growth factor receptor Kit	Kinase	P10721	KIT_HUMAN		Kd	5.20	CHEMBL
Serine/threonine-protein kinase B-raf	Kinase	P15056	BRAF_HUMAN		Kd	5.66	CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN		Kd	6.72	CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Kinase	P15735	PHKG2_HUMAN		Kd	6	CHEMBL
Myosin light chain kinase, smooth muscle	Kinase	Q15746	MYLK_HUMAN		Kd	6.44	CHEMBL
Death-associated protein kinase 3	Kinase	O43293	DAPK3_HUMAN		Kd	7.05	CHEMBL
Histone deacetylase 6	Enzyme	Q9UBN7	HDAC6_HUMAN		IC50	7.82	CHEMBL
Calcium/calmodulin-dependent protein kinase type 1	Kinase	Q14012	KCC1A_HUMAN		Kd	6.33	CHEMBL
Mitogen-activated protein kinase 8	Kinase	P45983	MK08_HUMAN		Kd	5.32	CHEMBL
Rho-associated protein kinase 1	Kinase	Q13464	ROCK1_HUMAN		Kd	7.22	CHEMBL
Serine/threonine-protein kinase PLK1	Kinase	P53350	PLK1_HUMAN		Kd	6.89	CHEMBL
Death-associated protein kinase 2	Kinase	Q9UIK4	DAPK2_HUMAN		Kd	7.01	CHEMBL
High affinity nerve growth factor receptor	Kinase	P04629	NTRK1_HUMAN		Kd	5.82	CHEMBL
Protein kinase C alpha type	Kinase	P17252	KPCA_HUMAN		Kd	4.78	CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit delta	Kinase	Q13557	KCC2D_HUMAN		Kd	7.05	CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit gamma	Kinase	Q13555	KCC2G_HUMAN		Kd	7	CHEMBL
AP2-associated protein kinase 1	Kinase	Q2M2I8	AAK1_HUMAN		Kd	6.92	CHEMBL
Serine/threonine-protein kinase MARK2	Kinase	Q7KZI7	MARK2_HUMAN		Kd	6.18	CHEMBL
Ribosomal protein S6 kinase alpha-2	Kinase	Q15349	KS6A2_HUMAN		Kd	6.82	CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit beta	Kinase	Q13554	KCC2B_HUMAN		Kd	6.51	CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform	Kinase	Q16816	PHKG1_HUMAN		Kd	5.24	CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha	Kinase	Q9UQM7	KCC2A_HUMAN		Kd	7.34	CHEMBL
Serine/threonine-protein kinase 17B	Kinase	O94768	ST17B_HUMAN		Kd	5.46	CHEMBL
Protein kinase C epsilon type	Kinase	Q02156	KPCE_HUMAN		Kd	6.28	CHEMBL
Serine/threonine-protein kinase PLK4	Kinase	O00444	PLK4_HUMAN		Kd	6.70	CHEMBL
Aurora kinase C	Kinase	Q9UQB9	AURKC_HUMAN		Kd	5.06	CHEMBL
Serine/threonine-protein kinase 16	Kinase	O75716	STK16_HUMAN		Kd	6.31	CHEMBL
Dual specificity protein kinase TTK	Kinase	P33981	TTK_HUMAN		Kd	6.32	CHEMBL
Serine/threonine-protein kinase N1	Kinase	Q16512	PKN1_HUMAN		Kd	5.52	CHEMBL
Serine/threonine-protein kinase 17A	Kinase	Q9UEE5	ST17A_HUMAN		Kd	5.21	CHEMBL
ALK tyrosine kinase receptor	Kinase	Q9UM73	ALK_HUMAN		Kd	5.82	CHEMBL
Ephrin type-A receptor 3	Kinase	P29320	EPHA3_HUMAN		Kd	5.21	CHEMBL
BMP-2-inducible protein kinase	Kinase	Q9NSY1	BMP2K_HUMAN		Kd	6.68	CHEMBL
Dual specificity protein kinase CLK1	Kinase	P49759	CLK1_HUMAN		Kd	5.49	CHEMBL
Dual specificity protein kinase CLK2	Kinase	P49760	CLK2_HUMAN		Kd	6.34	CHEMBL
Cyclin-G-associated kinase	Kinase	O14976	GAK_HUMAN		Kd	7	CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D	Kinase	Q8IU85	KCC1D_HUMAN		Kd	6.92	CHEMBL
Activated CDC42 kinase 1	Kinase	Q07912	ACK1_HUMAN		Kd	5.59	CHEMBL
Ribosomal protein S6 kinase alpha-5	Kinase	O75582	KS6A5_HUMAN		Kd	6.85	CHEMBL
Dual specificity protein kinase CLK4	Kinase	Q9HAZ1	CLK4_HUMAN		Kd	5.77	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2	Kinase	Q9HBH9	MKNK2_HUMAN		Kd	6.70	CHEMBL
MAP/microtubule affinity-regulating kinase 3	Kinase	P27448	MARK3_HUMAN		Kd	4.83	CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G	Kinase	Q96NX5	KCC1G_HUMAN		Kd	5.66	CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit beta	Kinase	O14920	IKKB_HUMAN		Kd	5.64	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1	Kinase	Q02750	MP2K1_HUMAN		Kd	5.72	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2	Kinase	P36507	MP2K2_HUMAN		Kd	5.40	CHEMBL
BDNF/NT-3 growth factors receptor	Kinase	Q16620	NTRK2_HUMAN		Kd	6.44	CHEMBL
Cyclin-dependent kinase 7	Kinase	P50613	CDK7_HUMAN		Kd	5.48	CHEMBL
Serine/threonine-protein kinase DCLK3	Kinase	Q9C098	DCLK3_HUMAN		Kd	6.59	CHEMBL
Ribosomal protein S6 kinase alpha-6	Kinase	Q9UK32	KS6A6_HUMAN		Kd	6.82	CHEMBL
NUAK family SNF1-like kinase 2	Kinase	Q9H093	NUAK2_HUMAN		Kd	6.49	CHEMBL
Non-receptor tyrosine-protein kinase TYK2	Kinase	P29597	TYK2_HUMAN		Ki	9.30	CHEMBL
Serine/threonine-protein kinase 25	Kinase	O00506	STK25_HUMAN		Kd	5.20	CHEMBL
Serine/threonine-protein kinase RIO1	Kinase	Q9BRS2	RIOK1_HUMAN		Kd	5.60	CHEMBL
NT-3 growth factor receptor	Kinase	Q16288	NTRK3_HUMAN		Kd	6.48	CHEMBL
Casein kinase II subunit alpha	Kinase	P68400	CSK21_HUMAN		Kd	5.38	CHEMBL
Casein kinase II subunit alpha'	Kinase	P19784	CSK22_HUMAN		Kd	5.48	CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Kinase	Q14164	IKKE_HUMAN		Kd	5.92	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3	Kinase	P46734	MP2K3_HUMAN		Kd	6.33	CHEMBL
Maternal embryonic leucine zipper kinase	Kinase	Q14680	MELK_HUMAN		Kd	5.66	CHEMBL
Serine/threonine-protein kinase 26	Kinase	Q9P289	STK26_HUMAN		Kd	5.51	CHEMBL
Serine/threonine-protein kinase Nek7	Kinase	Q8TDX7	NEK7_HUMAN		Kd	5.31	CHEMBL
Serine/threonine-protein kinase RIO3	Kinase	O14730	RIOK3_HUMAN		Kd	5.70	CHEMBL
SRSF protein kinase 1	Kinase	Q96SB4	SRPK1_HUMAN		Kd	5.68	CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1	Kinase	Q8NFD2	ANKK1_HUMAN		Kd	6.41	CHEMBL
Myotonin-protein kinase	Kinase	Q09013	DMPK_HUMAN		Kd	5.46	CHEMBL
Leukocyte tyrosine kinase receptor	Kinase	P29376	LTK_HUMAN		Kd	6.36	CHEMBL
Serine/threonine-protein kinase PAK 6	Kinase	Q9NQU5	PAK6_HUMAN		Kd	5.54	CHEMBL
Serine/threonine-protein kinase PAK 7	Kinase	Q9P286	PAK5_HUMAN		Kd	5.89	CHEMBL
Bone morphogenetic protein receptor type-2	Kinase	Q13873	BMPR2_HUMAN		Kd	6.03	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4	Kinase	P45985	MP2K4_HUMAN		Kd	5.74	CHEMBL
Calcium/calmodulin-dependent protein kinase type IV	Kinase	Q16566	KCC4_HUMAN		Kd	6.71	CHEMBL
Mitogen-activated protein kinase kinase kinase 11	Kinase	Q16584	M3K11_HUMAN		Kd	5.72	CHEMBL
Citron Rho-interacting kinase	Kinase	O14578	CTRO_HUMAN		Kd	4.80	CHEMBL
Casein kinase I isoform gamma-1	Kinase	Q9HCP0	KC1G1_HUMAN		Kd	6.07	CHEMBL
Death-associated protein kinase 1	Kinase	P53355	DAPK1_HUMAN		Kd	7.14	CHEMBL
Serine/threonine-protein kinase DCLK1	Kinase	O15075	DCLK1_HUMAN		Kd	7.17	CHEMBL
Serine/threonine-protein kinase DCLK2	Kinase	Q8N568	DCLK2_HUMAN		Kd	6.12	CHEMBL
Serine/threonine-protein kinase PAK 4	Kinase	O96013	PAK4_HUMAN		Kd	5.80	CHEMBL
Serine/threonine-protein kinase PLK3	Kinase	Q9H4B4	PLK3_HUMAN		Kd	6.15	CHEMBL
cGMP-dependent protein kinase 2	Kinase	Q13237	KGP2_HUMAN		Kd	6.16	CHEMBL
Ribosomal protein S6 kinase alpha-1	Kinase	Q15418	KS6A1_HUMAN		Kd	6.92	CHEMBL
Ribosomal protein S6 kinase alpha-4	Kinase	O75676	KS6A4_HUMAN		Kd	6.47	CHEMBL
Casein kinase I isoform alpha	Kinase	P48729	KC1A_HUMAN		Kd	5.74	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2	Kinase	Q12851	M4K2_HUMAN		Kd	5.70	CHEMBL
Serine/threonine-protein kinase TBK1	Kinase	Q9UHD2	TBK1_HUMAN		Kd	5.77	CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Kinase	Q13627	DYR1A_HUMAN		Kd	6.04	CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 2	Kinase	Q92630	DYRK2_HUMAN		Kd	5.43	CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN		Kd	5.51	CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1	Kinase	O75460	ERN1_HUMAN		Kd	5.60	CHEMBL
Rhodopsin kinase	Kinase	Q15835	RK_HUMAN		Kd	6.14	CHEMBL
G protein-coupled receptor kinase 4	Kinase	P32298	GRK4_HUMAN		Kd	5.21	CHEMBL
G protein-coupled receptor kinase 7	Kinase	Q8WTQ7	GRK7_HUMAN		Kd	6.27	CHEMBL
Homeodomain-interacting protein kinase 2	Kinase	Q9H2X6	HIPK2_HUMAN		Kd	6	CHEMBL
Homeodomain-interacting protein kinase 3	Kinase	Q9H422	HIPK3_HUMAN		Kd	5.92	CHEMBL
Interleukin-1 receptor-associated kinase 1	Kinase	P51617	IRAK1_HUMAN		Kd	6.54	CHEMBL
Mitogen-activated protein kinase kinase kinase 2	Kinase	Q9Y2U5	M3K2_HUMAN		Kd	7.39	CHEMBL
Mitogen-activated protein kinase kinase kinase 3	Kinase	Q99759	M3K3_HUMAN		Kd	6.82	CHEMBL
Microtubule-associated serine/threonine-protein kinase 1	Kinase	Q9Y2H9	MAST1_HUMAN		Kd	6.28	CHEMBL
Serine/threonine-protein kinase OSR1	Kinase	O95747	OXSR1_HUMAN		Kd	5.57	CHEMBL
Serine/threonine-protein kinase RIO2	Kinase	Q9BVS4	RIOK2_HUMAN		Kd	5.92	CHEMBL
SRSF protein kinase 3	Kinase	Q9UPE1	SRPK3_HUMAN		Kd	5.48	CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase	Kinase	Q9UEW8	STK39_HUMAN		Kd	5.72	CHEMBL
Mitogen-activated protein kinase kinase kinase 7	Kinase	O43318	M3K7_HUMAN		Kd	6.14	CHEMBL
Serine/threonine-protein kinase TAO1	Kinase	Q7L7X3	TAOK1_HUMAN		Kd	5.89	CHEMBL
Serine/threonine-protein kinase TAO3	Kinase	Q9H2K8	TAOK3_HUMAN		Kd	6.23	CHEMBL
Serine/threonine-protein kinase ULK1	Kinase	O75385	ULK1_HUMAN		Kd	6.52	CHEMBL
Serine/threonine-protein kinase ULK2	Kinase	Q8IYT8	ULK2_HUMAN		Kd	6.72	CHEMBL
Serine/threonine-protein kinase ULK3	Kinase	Q6PHR2	ULK3_HUMAN		Kd	5.62	CHEMBL
Mitogen-activated protein kinase kinase kinase 19	Kinase	Q56UN5	M3K19_HUMAN		Kd	6.57	CHEMBL
Homeodomain-interacting protein kinase 1	Kinase	Q86Z02	HIPK1_HUMAN		Kd	5.92	CHEMBL
Mitogen-activated protein kinase kinase kinase 15	Kinase	Q6ZN16	M3K15_HUMAN		Kd	5.96	CHEMBL
Serine/threonine-protein kinase PLK2	Kinase	Q9NYY3	PLK2_HUMAN		Kd	5.82	CHEMBL
Receptor-interacting serine/threonine-protein kinase 4	Kinase	P57078	RIPK4_HUMAN		Kd	5.68	CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3	Kinase	P0C264	SBK3_HUMAN		Kd	5.24	CHEMBL
Mitogen-activated protein kinase kinase kinase 1	Kinase	Q13233	M3K1_HUMAN		Kd	5.38	CHEMBL
Phosphatidylinositol 4-kinase beta	Kinase	Q9UBF8	PI4KB_HUMAN		Kd	5.47	CHEMBL
Serine/threonine-protein kinase SIK3	Kinase	Q9Y2K2	SIK3_HUMAN		Kd	5.89	CHEMBL
Bone morphogenetic protein receptor type-1B	Kinase	O00238	BMR1B_HUMAN		Kd	5.74	CHEMBL
Serine/threonine-protein kinase SBK1	Kinase	Q52WX2	SBK1_HUMAN		Kd	5.89	CHEMBL
Serine/threonine-protein kinase Nek3	Kinase	P51956	NEK3_HUMAN		Kd	5.96	CHEMBL
Peripheral plasma membrane protein CASK	Kinase	O14936	CSKP_HUMAN		Kd	5.82	CHEMBL
Serine/threonine-protein kinase VRK2	Kinase	Q86Y07	VRK2_HUMAN		Kd	5.40	CHEMBL
Serine/threonine-protein kinase TAO2	Kinase	Q9UL54	TAOK2_HUMAN		Kd	6.51	CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2	Kinase	Q5S007	LRRK2_HUMAN		Kd	7.05	CHEMBL
JAK2/JAK1	Kinase	O60674 P23458	JAK2_HUMAN JAK1_HUMAN		IC50	7.51	CHEMBL
JAK3/JAK1	Kinase	P23458 P52333	JAK1_HUMAN JAK3_HUMAN		IC50	7.64	CHEMBL
JAK1/TYK2	Kinase	P23458 P29597	JAK1_HUMAN TYK2_HUMAN		IC50	6.71	CHEMBL
JAK1/JAK2/TYK2	Kinase	O60674 P23458 P29597	JAK2_HUMAN JAK1_HUMAN TYK2_HUMAN		IC50	6.53	CHEMBL
JAK2/TYK2	Kinase	O60674 P29597	JAK2_HUMAN TYK2_HUMAN		IC50	6.09	CHEMBL
Oxysterols receptor LXR-beta	Nuclear other	P55055	NR1H2_HUMAN		Ki	4.35	CHEMBL
Uncharacterized protein FLJ45252	Unclassified	Q6ZSR9	YJ005_HUMAN		Kd	6.71	CHEMBL
STE20-related kinase adapter protein alpha	Kinase	Q7RTN6	STRAA_HUMAN		Kd	5.43	CHEMBL
Rho-associated protein kinase 2	Kinase	O75116	ROCK2_HUMAN		Kd	7.28	CHEMBL
MAP kinase-activated protein kinase 5	Kinase	Q8IW41	MAPK5_HUMAN		Kd	5.51	CHEMBL
Tyrosine-protein kinase JAK3	Kinase	P52333	JAK3_HUMAN		Kd	8.70	CHEMBL
Tyrosine-protein kinase JAK2	Kinase		JAK2_MOUSE		EC50	6.73	CHEMBL
Serine/threonine-protein kinase PknB	Kinase		PKNB_MYCTU		Kd	5.38	CHEMBL

External reference:

ID	Source
4031235	VUID
N0000184017	NUI
D09959	KEGG_DRUG
1092939-17-7	SECONDARY_CAS_RN
4031235	VANDF
C2931926	UMLSCUI
CHEBI:66919	CHEBI
RXT	PDB_CHEM_ID
CHEMBL1789941	ChEMBL_ID
CHEMBL1795071	ChEMBL_ID
DB08877	DRUGBANK_ID
C540383	MESH_SUPPLEMENTAL_RECORD_UI
5688	IUPHAR_LIGAND_ID
9287	INN_ID
82S8X8XX8H	UNII
25126798	PUBCHEM_CID
1193325	RXNORM
186162	MMSL
28206	MMSL
39982	MMSL
d07812	MMSL
014040	NDDF
014041	NDDF
702806008	SNOMEDCT_US
703779004	SNOMEDCT_US
734494005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-005	TABLET	5 mg	ORAL	NDA	29 sections
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-005	TABLET	5 mg	ORAL	NDA	29 sections
OPZELURA	HUMAN PRESCRIPTION DRUG LABEL	1	50881-007	CREAM	15 mg	TOPICAL	NDA	28 sections
OPZELURA	HUMAN PRESCRIPTION DRUG LABEL	1	50881-007	CREAM	15 mg	TOPICAL	NDA	28 sections
OPZELURA	HUMAN PRESCRIPTION DRUG LABEL	1	50881-007	CREAM	15 mg	TOPICAL	NDA	28 sections
OPZELURA	HUMAN PRESCRIPTION DRUG LABEL	1	50881-007	CREAM	15 mg	TOPICAL	NDA	28 sections
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-010	TABLET	10 mg	ORAL	NDA	29 sections
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-010	TABLET	10 mg	ORAL	NDA	29 sections
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-015	TABLET	15 mg	ORAL	NDA	29 sections
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-015	TABLET	15 mg	ORAL	NDA	29 sections
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-020	TABLET	20 mg	ORAL	NDA	29 sections
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-020	TABLET	20 mg	ORAL	NDA	29 sections
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-025	TABLET	25 mg	ORAL	NDA	29 sections
JAKAFI	HUMAN PRESCRIPTION DRUG LABEL	1	50881-025	TABLET	25 mg	ORAL	NDA	29 sections